Company: LIMN
Filing Date: 2025-01-16
Form Type: POS AM
Source: 0001104659-25-003835
Chunk: 191

Company: Liminatus Pharma, Inc.
Filing Date: 2025-01-16
Form: POS AM
Chunk 191
---
 comply with Nasdaq’s initial listing requirements, which are more rigorous than Nasdaq’s continued listing requirements, in order to maintain the listing of ParentCo’s securities on Nasdaq. Iris cannot assure you that ParentCo will be able to meet those initial listing requirements or obtain all the necessary approvals. Failure to obtain the necessary approvals will result in the failure of the Business Combination to be consummated. If Nasdaq does not agree to list ParentCo’s securities for trading on its exchange and ParentCo is not able to list its securities on another national securities exchange, Iris expects ParentCo’s securities could be quoted on an over-the-counter market. If this were to occur, ParentCo could face significant material adverse consequences, including:

•

a limited availability of market quotations for ParentCo’s securities;

•

reduced liquidity for ParentCo’s securities;

•

a determination that ParentCo’s common stock is a “penny stock” which will require brokers trading in ParentCo’s common stock to adhere to more stringent rules and possibly result in a reduced level of trading activity in the secondary trading market for ParentCo’s securities;

•

a limited amount of news and analyst coverage; and

•

a decreased ability to issue additional securities or obtain additional financing in the future.

The delisting of our securities from Nasdaq may have a material adverse effect on the trading and price of our securities.

On September 6, 2024, our securities were delisted from Nasdaq. The delisting of our securities from Nasdaq may have a material adverse effect on us, including:

•

a limited availability of market quotations for our securities;

•

reduced liquidity of our securities;

•

a determination that our securities are a “penny stock” which will require brokers trading in our securities to adhere to more stringent rules and possibly result in a reduced level of trading activity in the secondary trading market for our securities;

•

a limited amount of news and analyst coverage;

•

a decreased ability to issue additional securities or obtain additional financing in the future;

•

a decrease in the market price of our securities;

•

a decrease in the number of institutional and other investors that will consider investing in our securities; and

•

a decrease in the number of broker-dealers willing to execute trades in our securities.

The lack of an active trading market may limit the liquidity of an investment in our securities, meaning you may not be able to sell our securities you own at times, or at prices, attractive to you. Any of these factors may materially and adversely affect the price of our securities.

<div align